RBCC: TheraKine Joint Venture Offers Significant Opportunity in Licensing
RBCC: TheraKine Joint Venture Offers Significant Opportunity in Licensing
NOKOMIS, Fla.--(BUSINESS WIRE)-- Only days after signing a joint venture agreement with cutting-edge drug delivery innovators TheraKine, Rainbow BioSciences, the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC) is working hard to ensure that the partnership will be a fruitful one. Already, the company is searching for new targets that would benefit from adding licenses for the drug delivery protocols TheraKine and RBCC plan to roll out.
The global market for drug delivery technologies is driven by biologics and medications that can't be administered effectively through traditional means. Some experts believe that the worldwide market for the 10 most popular drug delivery technologies (DDTs) alone could grow to $81.5 billion by 2015.
In order to capture a piece of that growth, RBCC is seeking out healthcare providers for whom TheraKine's advanced sustained-release delivery system could yield significant returns for their clients. TheraKine has developed and patented novel, tunable technologies with the potential to enable selective, site-specific drug delivery, allowing for lower drug concentrations and significantly reducing the risk of drug toxicity.
"Licensing this incredible new platform is going to be one of the key opportunities to making this a successful partnership," said RBCC CEO Patrick Brown. "It's a top priority for our company moving forward. The potential is limitless."
Rainbow BioSciences develops and markets new medical and research technology innovations to compete in a fast-growing industry alongside companies such as Bristol Myers Squibb Co. (NYS: BMY) , Biogen Idec Inc. (NAS: BIIB) , Abbott Laboratories (NYS: ABT) and Valeant Pharmaceuticals International (NYS: VRX) .
RBCC is dedicated to delivering new medical research and technologies to a hungry global marketplace. For more information on RBCC's initiatives, please visit www.rainbowbiosciences.com/investors.html.
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
About TheraKine Ltd.
TheraKine Ltd. is a privately held platform technology company with laboratories in Berlin (Germany). TheraKine provides innovative reformulation to enable sustained release for pharmaceutical and biological companies worldwide.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Rainbow Coral Corp.
Patrick Brown, 813-367-9511
President and CEO
info@rainbowcoral.com
KEYWORDS: United States North America Florida
INDUSTRY KEYWORDS:
The article RBCC: TheraKine Joint Venture Offers Significant Opportunity in Licensing originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
